Acarix AB (publ) (ACARIX) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Acarix Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.016 Good morning and welcome to the Acarix 2025 00:00:03.016 -- 00:00:08.245 Q4 earnings call. Thanks for joining. As a reminder to shareholders as well 00:00:08.245 -- 00:00:12.071 as new shareholders, I want to give a little bit about what we do and how we do it. 00:00:12.071 -- 00:00:17.741 So we are Acarix with the CADS4 device, which is a high fidelity point of care diagnostic 00:00:17.741 -- 00:00:21.647 that helps to risk stratify patients with coronary artery disease symptoms like low to 00:00:21.647 -- 00:00:23.656 moderate chest pain or shortness of breath. 00:00:23.656 -- 00:00:28.827 We have quickly and easily risk-ratified patients with a 96.2% negative predictive 00:00:28.827 -- 00:00:33.757 value, which is on par or better than a number of more invasive testing that has procured 00:00:33.757 -- 00:00:38.967 for today. We have over 15 years of R&D, over 6,000 patients in clinical 00:00:38.967 -- 00:00:44.277 trials, 45 patents worldwide, and over 60,000 assessments to date. 00:00:44.277 -- 00:00:49.168 We are CE marked, FDA de novo cleared, and we're designated a class two medical device. 00:00:49.168 -- 00:00:54.160 We do have a CPT code in the United States for reimbursement, and we are headquartered 00:00:54.160 -- 00:00:59.788 in Sweden with our production in Copenhagen, and we have a focus on global sales. 00:00:59.973 -- 00:01:04.719 A little bit about our executive summary highlighting what we did in Q4 of 2025. 00:01:05.000 -- 00:01:08.044 We had revenue increase of 26%, 00:01:08.044 -- 00:01:11.808 which is pretty exciting to us, driven by 87% growth in the U.S. 00:01:11.808 -- 00:01:15.452 market, which is our most important market and our strategic focus. 00:01:15.452 -- 00:01:19.216 Our cash score deliveries g...